Abstract

Diabetic foot osteomyelitis (DFO) is a highly morbid condition that commonly affects diabetic patients. Biodegradable calcium-sulfate antibiotic beads (CaSO4) are theoretical adjuvant agents to reduce morbidity in DFO. However, there is a paucity of research on the safety and effectiveness of CaSO4 beads in DFO.Therefore, the purpose of this study was to assess the safety and effectiveness of CaSO4 beads in different DFO locations. We conducted a retrospective cohort study between January 1, 2015 and January 1, 2022 of patients with DFO who underwent surgical intervention and adjuvant CaSO4 beads placement.The location of DFO was determined based on the forefoot, midfoot, or hindfoot locations.Outcomes measured were ulcer-free time points of three and six months as well as recurrence of DFO at 12 months.Safety was also evaluated with incidences of acute kidney injury, wound drainage, and hypercalcemia. Forty-five cases were included. Of these, only 9/45 (20%) and 13/45 (29%) were ulcer-free at three months and six months, respectively.DFO recurred in 19/45 (42%) patients.Safety outcomes were significant for wound drainage (62%) and acute kidney injury (9%).Stratifying according to the location of DFO showed no statistically significant difference in outcomes. In this cohort study, adjuvant CaSO4 beads showed high rates of ulcer persistence and DFO recurrence. Given the limited benefits seen here and the potential for high rates of wound drainage, the use of adjuvant CaSO4 beads should be used cautiously until a multicenter randomized clinical trial is conducted to definitely evaluate the safety and effectiveness of CaSO4 beads in DFO.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call